Placebo to Keytruda - Normal saline
Sponsors
Merck Sharp & Dohme LLC
Conditions
Adjuvant treatment of HCCLocally recurrent inoperable or metastatic HR+/HER2- breast cancerMuscle Invasive Bladder CancerResected High-Risk Stage II Melanomawhich has not been previously treated with cytotoxic chemotherapy in the noncurative setting
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
Active, not recruitingCTIS2023-503500-87-00
Start: 2020-03-17Target: 181Updated: 2025-08-19
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
CompletedCTIS2022-501971-24-00
Start: 2019-05-20End: 2025-07-29Target: 260Updated: 2025-09-05
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
Active, not recruitingCTIS2022-501966-23-00
Start: 2018-09-11Target: 530Updated: 2026-01-12
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
Active, not recruitingCTIS2023-506752-24-00
Start: 2021-08-05Target: 177Updated: 2025-09-03